Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CODEXIS, INC. updated its the quarter ended June 30, 2023 guidance (reaffirmed).
- Period
- the quarter ended June 30, 2023
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
On July 20, 2023 Codexis, Inc. (the “Company”) announced certain of its preliminary unaudited financial results for the quarter ended June 30, 2023, reiterated and provided new financial guidance
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
CODEXIS, INC. announced a restructuring with charges of approximately $2.9 million (approximately 25%).
- Type
- restructuring
- Charge
- approximately $2.9 million
- Headcount
- approximately 25%
Exact text from the filing
On July 20, 2023, in alignment with its enhanced strategic focus, the Company publicly announced and informed its employees that it was implementing a workforce reduction of approximately 25%. This measure was implemented in support of the Company’s organizational streamlining to focus on the continued advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide (ECO) SynthesisTM platform and its highly complementary Pharmaceutical Manufacturing business. The Company expects the payment of post-employment benefits to impacted employees, as well as the payment of other expenses such as related tax costs, will result in the Company recording an expense of approximately $2.9 million.
View on SEC.gov